SCHEMBL22014479

SCHEMBL22014479

O=P(O)(CO)CN1CCN(Cc2ccccc2)CCN(CP(=O)(O)CO)CC1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.58
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HDAC4 P56524 1/20 0.51
KCNH2 Q12809 1/20 0.51
HDAC1 Q13547 1/20 0.51
MC4R P32245 1/20 0.50
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
DRD4 P21917 1/20 0.49
POLB P06746 1/20 0.49
HTR1A P08908 1/20 0.48
HTR7 P34969 1/20 0.48
KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22014483 0.86 SIGMAR1 (0.56) SIGMAR1ALDH1A1SMN1; SMN2HDAC4KCNH2
SCHEMBL22014090 0.85 HDAC1 (0.50) ALDH1A1SMN1; SMN2HDAC4KCNH2HDAC1
SCHEMBL22014091 0.85 SIGMAR1 (0.64) SIGMAR1ALDH1A1SMN1; SMN2HDAC4KCNH2
SCHEMBL22014474 0.82 SIGMAR1 (0.51) SIGMAR1ALDH1A1SMN1; SMN2HDAC4KCNH2
SCHEMBL22014478 0.81 POLB (0.58) SIGMAR1ALDH1A1SMN1; SMN2HDAC4KCNH2
SCHEMBL22014093 0.81 SIGMAR1 (0.58) SIGMAR1ALDH1A1SMN1; SMN2HDAC4KCNH2
SCHEMBL22355488 0.80 SIGMAR1 (0.49) SIGMAR1ALDH1A1SMN1; SMN2HDAC4KCNH2
SCHEMBL8188324 0.76 SIGMAR1 (1.00) SIGMAR1MC4RKMT2ALMNADRD4
SCHEMBL22014095 0.76 FAAH (0.55) SIGMAR1ALDH1A1SMN1; SMN2HDAC4KCNH2
SCHEMBL2489199 0.76 SIGMAR1 (1.00) SIGMAR1MC4RKMT2ALMNADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022204065-A1 IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-09-29 WO disclosed
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-05-31 US disclosed
WO-2020102820-A1 COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups SLC40A1, TAC3, ABCB7 SIGMAR1 1907/4885ALDH1A1 4407/4885SMN1; SMN2 3358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.